Pfizer: Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib)…
Pfizer Inc. (NYSE:PFE) announced today the presentation of real-world evidence demonstrating an associated benefit for patients treated with IBRANCE® (palbociclib) in combination with an aromatase inhibitor (AI), as compared to AI alone,!-->…